Brief: Mannkind To Proceed With Phase 1 Nintedanib Dpi Study For Pulmonary Fibrotic Diseases
30/04/2024 11:17
April 30 (Reuters) - MannKind Corp MNKD.O :
* MANNKIND TO PROCEED WITH PHASE 1 NINTEDANIB DPI (MNKD-201)
STUDY
FOR PULMONARY FIBROTIC DISEASES
* MANNKIND CORP: ENROLLMENT OF FIRST STUDY PARTICIPANT
ANTICIPATED
IN JUNE
Source text for Eikon: ID:nGNX2wk3s5
Further company coverage: MNKD.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children